Curacin A

Curacin A

SCHEMBL61304

C=CC[C@@H](CC/C(C)=C/C=C/CC/C=C\[C@@H]1CSC([C@@H]2C[C@@H]2C)=N1)OC

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
TUBB4A P04350 20/20 1.00
TUBB P07437 20/20 1.00
TUBA3C P0DPH7 20/20 1.00
TUBA1B P68363 20/20 1.00
TUBA4A P68366 20/20 1.00
TUBB4B P68371 20/20 1.00
TUBB3 Q13509 20/20 1.00
TUBB2A Q13885 20/20 1.00
TUBB8 Q3ZCM7 20/20 1.00
TUBA3E Q6PEY2 20/20 1.00
TUBA1A Q71U36 20/20 1.00
TUBA1C Q9BQE3 20/20 1.00
TUBB6 Q9BUF5 20/20 1.00
TUBB2B Q9BVA1 20/20 1.00
TUBB1 Q9H4B7 20/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Curacin A SCHEMBL14363315 1.00 TUBB4A (1.00) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
Curacin A SCHEMBL12379192 1.00 TUBB4A (1.00) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL13135120 0.91 TUBB4A (0.82) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL13857390 0.90 TUBB4A (0.82) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL29884561 0.88 TUBB4A (1.00) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL12735921 0.62 TUBB4A (0.48) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL2108688 0.51
SCHEMBL13764202 0.51 TUBB4A (0.40) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL1775924 0.50
SCHEMBL5058608 0.50 CNR1 (0.41) TUBB4ATUBBTUBA3CTUBA1BTUBA4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 7999 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260116861-A1 ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) 2026-04-30 US claimed
US-12522572-B2 Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) 2026-01-13 US claimed
EP-4479042-A1 CANCER TREATMENT BY COMBINED INHIBITION OF POLO-LIKE KINASE AND MICROTUBULE POLYMERIZATION MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2024-12-25 EP claimed
US-20240400468-A1 Bionutritional Compositions for Plants and Soils ENVIROKURE, INCORPORATED (US) 2024-12-05 US claimed
US-20240343697-A1 ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) 2024-10-17 US claimed
EP-4377280-A1 BIONUTRITIONAL COMPOSITIONS FOR PLANTS AND SOILS Envirokure Incorporated (US) 2024-06-05 EP claimed
WO-2023158514-A1 CANCER TREATMENT BY COMBINED INHIBITION OF POLO-LIKE KINASE AND MICROTUBULE POLYMERIZATION MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2023-08-24 WO claimed
US-20230263783-A1 CANCER TREATMENT BY COMBINED INHIBITION OF POLO-LIKE KINASE AND MICROTUBULE POLYMERIZATION MASSACHUSETTS INSTITUTE OF TECHNOLOGY 2023-08-24 US claimed
WO-2023009636-A1 BIONUTRITIONAL COMPOSITIONS FOR PLANTS AND SOILS ENVIROKURE, INCORPORATED (US) 2023-02-02 WO claimed
US-11345956-B2 Methods and compositions related to prostate cancer therapeutics THE JOHNS HOPKINS UNIVERSITY (US) 2022-05-31 US claimed
US-20060018933-A1 Novel drug delivery system TORRENT PHARMACEUTICALS LIMITED (IN) 2006-01-26 US claimed
US-20040092583-A1 Treatment for inhibiting neoplastic lesions SHANAHAN-PRENDERGAST ELIZABETH (IE) 2004-05-13 US claimed
EP-1351678-A2 TREATMENT FOR INHIBITING NEOPLASTIC LESIONS USING INCENSOLE AND/OR FURANOGERMACRENS Shanahan-Prendergast, Elizabeth (IE) 2003-10-15 EP claimed
EP-1336602-A1 Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases Scaramuzzino, Giovanni (IT) 2003-08-20 EP claimed
WO-2002053138-A2 TREATMENT FOR INHIBITING NEOPLASTIC LESIONS USING INCENSOLE AND/OR FURANOGERMACRENS SHANAHAN-PRENDERGAST ELISABETH (IE) 2002-07-11 WO claimed
US-20020037918-A1 Synthesis and biological evaluation of analogs of the antimitotic marine natural product curacin A NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2002-03-28 US claimed
WO-2002006267-A2 SYNTHESIS AND BIOLOGICAL EVALUATION OF ANALOGS OF THE ANTIMITOTIC MARINE NATURAL PRODUCT CURACIN A UNIVERSITY OF PITTSBURGH (US) 2002-01-24 WO claimed
WO-2000035865-A2 TUBULIN-BINDING AGENTS TULARIK INC. (US) 2000-06-22 WO claimed
WO-1995009630-A1 COMPOUNDS EXHIBITING ANTIPROLIFERATIVE ACTIVITY AGAINST CELLS THE STATE OF OREGON ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION ON BEHALF OF OREGON STATE UNIVERSITY (US) 1995-04-13 WO claimed
US-5324739-A Curacin A and Curacin B isomers; antimitotics STATE OF OREGON ACTING BY AND THROUGH THE STATE BOARD OF HIGHER EDUCATION ON BEHALF OF OREGON STATE UNIVERSITY (US) 1994-06-28 US claimed